On March 28th, the journal "Cell" published an online research paper titled "Flexible Scaffold-based Cheminformatics Approach for Polypharmacological Drug Design".

X4 Pharmaceuticals announced preliminary results from its Phase 2 trial evaluating the safety and efficacy of once-daily oral mavorixafor with or without injected G-CSF in patients with idiopathic, cyclic, or congenital neutropenia.

Deucrictibant is a new, potent oral small-molecule bradykinin B2 receptor antagonist, originally developed by the Pharvaris team.

AstraZeneca's Novel GR/β2AR Targeted Therapy for Asthma: Airsupra Approval and Its Implications for Treatment.

TransCon PTH, developed by Ascendis Pharma, is an investigational prodrug of PTH hormone undergoing research and development.

Idiopathic Pulmonary Fibrosis (IPF) is a progressive lung condition causing scarring and stiffness, which makes breathing harder over time.

Advancing GPCR-Targeted Therapy: Tectonic Therapeutics' GEODe Platform Overcomes Discovery Challenges.

Gut-Derived Hormone Cholesin Found to Regulate Cholesterol Metabolism.

On March 22, Johnson & Johnson announced FDA approval of OPSYNVI®, their new drug for treating WHO Group 1 PAH and class II-III PAH in adults. OPSYNVI® combines macitentan and tadalafil in a single tablet.

Recently, AstraZeneca reported in detail the discovery process of the RXFP1 agonist AZD5462, currently in Phase II clinical trials, in two consecutive articles published in the top-tier journal JMC (Journal of Medicinal Chemistry).

On March 18th, Bristol Myers Squibb (BMS) finalized its acquisition of Karuna Therapeutics, enhancing its neuroscience investments. Karuna has stopped NASDAQ trading and is now fully owned by BMS.

Sumitomo Dainippon Pharma and its U.S. subsidiary SMPA announced an updated agreement on March 15th with Otsuka Pharmaceutical for the joint development of four psychiatric and neurological compounds, including ulotaront and others, amending their original September 30, 2021, partnership.